Capmatinib OverviewCapmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite. ...
Read more Capmatinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Capmatinib
Recent Capmatinib Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 150mg, 200mg
Other drugs which contain Capmatinib or a similar ingredient: (1 result)
- TABRECTA Capmatinib Hydrochloride